Dolutegravir/rilpivirine

Dolutegravir/rilpivirine
Combination of
DolutegravirHIV integrase strand transfer inhibitor (INSTI)
RilpivirineHIV nonnucleoside reverse transcriptase inhibitor (NNRTI)
Names
Trade namesJuluca
Clinical data
Main usesHIV/AIDS[1]
Side effectsDiarrhea, nausea, headache[1]
Pregnancy
category
  • AU: B1[2]
  • US: N (Not classified yet)[2]
    Routes of
    use    		By mouth
    External links
    AHFS/Drugs.comMonograph
    US NLMDolutegravir/rilpivirine
    Legal
    License data
    Legal status
    • UK: POM (Prescription only) [3]
    • US: ℞-only
    • EU: Rx-only
    • In general: ℞ (Prescription only)

    Dolutegravir/rilpivirine, sold under the brand name Juluca, is a combination medication used to treat HIV/AIDS.[1] It is generally only used in people who have been stabilized on other treatments.[4] It may be the only medication a person requires.[1] It is taken by mouth daily with food.[1]

    Common side effects include diarrhea, nausea, and headache.[1] Other side effects may include allergic reactions, liver problems, and depression.[1] Use in early pregnancy may harm the baby.[1] It contains dolutegravir, an integrase inhibitor, and rilpivirine, a reverse-transcriptase inhibitor.[1]

    The combination was approved for medical use in the United States in 2017 and Europe in 2018.[1][5] In the United Kingdom a month of medication costs the NHS about £700 as of 2021.[6] This amount in the United States is about 2,900 USD.[7]

    Medical uses

    Dosage

    It is taken at a dose of 50mg dolutegravir/25mg rilpivirine once per day.[6]

    References

    1. 1 2 3 4 5 6 7 8 9 10 "Juluca- dolutegravir sodium and rilpivirine hydrochloride tablet, film coated". DailyMed. 24 October 2019. Archived from the original on 12 June 2020. Retrieved 25 March 2020.
    2. 1 2 "Dolutegravir / rilpivirine (Juluca) Use During Pregnancy". Drugs.com. 7 January 2020. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
    3. ↑ "Juluca 50 mg/25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 25 February 2020. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
    4. ↑ "Dolutegravir and Rilpivirine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 27 December 2021.
    5. ↑ "Juluca EPAR". European Medicines Agency (EMA). 11 February 2019. Archived from the original on 25 March 2020. Retrieved 25 March 2020.
    6. 1 2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 681. ISBN 978-0857114105.
    7. ↑ "Juluca Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.